Seriously, this was a badly conceived blog apart from the manifold English mistakes. The thesis that Teva’s Lovenox ANDA is a hedge against loss of Copaxone exclusivity is just plain silly, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”